Recent Finacing
Recent Raise
Bolden Therapeutics develops antisense oligonucleotides to promote neurogenesis for CNS disorders including Alzheimer’s, conducting in vivo testing and advancing preclinical programs from Brown-origin research housed at Tufts Launchpad.
